Effect of the micro-immunotherapy medicine 2LPARK^® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease

References

• Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology. 2010;75(14):1270–1276. doi:10.1212/WNL.0b013e3181f6131120921512
   PubMed Web of Science ®Google Scholar
• Goswami P, Joshi N, Singh S. Neurodegenerative signaling factors and mechanisms in Parkinson’s pathology. Toxicol In Vitro. 2017;43:104–112. doi:10.1016/j.tiv.2017.06.00828627426
   PubMed Web of Science ®Google Scholar
• Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984;16(3):278–282. doi:10.1002/ana.4101603036333204
   PubMed Web of Science ®Google Scholar
• Barone P. Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol. 2010;17(3):364–376. doi:10.1111/j.1468-1331.2009.02900.x20050885
   PubMed Web of Science ®Google Scholar
• Segura‐Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA. Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem. 2014;129(6):898–915. doi:10.1111/jnc.1268624548101
   PubMed Web of Science ®Google Scholar
• Brieger K, Schiavone S, Miller FJ Jr, Krause KH. Reactive oxygen species: from health to disease. Swiss Med Wkly. 2012;142:w13659.22903797
   PubMed Web of Science ®Google Scholar
• Choi Y, Cho K, Yoon S, Lee H, Choi Y. A case of paraquat intoxication caused by intravenous injection. Am J Emerg Med. 2008;26(7):836–e3. doi:10.1016/j.ajem.2007.12.016
   Google Scholar
• Langston JW, Ballard PA Jr. Parkinson’s disease in a chemist working with l-methyl-4-phenyl-l, 2, 5, 6-tetrahydropyridine. N Engl J Med. 1983;309(5):310.
   Web of Science ®Google Scholar
• Lotharius J, O’Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation A novel mechanism of toxicity. J Biol Chem. 2000;275(49):38581–38588. doi:10.1074/jbc.M00538520010969076
   PubMed Web of Science ®Google Scholar
• Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci. 2005;25(26):6251–6259. doi:10.1523/JNEUROSCI.4601-04.200515987955
   PubMed Web of Science ®Google Scholar
• Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, Gerhardt GA. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol. 2005;58(2):224–233. doi:10.1002/ana.2054916049934
   PubMed Web of Science ®Google Scholar
• Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res. 2005;58(2):297. doi:10.1203/01.pdr.0000183658.17854.2816055937
   PubMed Web of Science ®Google Scholar
• Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson’s disease. Neurosci Lett. 2001;316(3):129–132.11744219
   PubMed Web of Science ®Google Scholar
• Asai K, Nakanishi K, Isobe I, et al. Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor. J Biol Chem. 1992;267(28):20311–20316.1400349
   PubMed Web of Science ®Google Scholar
• Thomas G, Cluzel H, Lafon J, Bruhwyler J, Lejeune B. Efficacy of 2LPAPI®, a micro-immunotherapy drug, in patients with high-risk papillomavirus genital infection. AID. 2016;6(01):7–14. doi:10.4236/aid.2016.61002
   Google Scholar
• Floris I, Lechner J, Lejeune B. Follow-up of patients with systemic immunological diseases undergoing fatty-degenerative osteolysis of the jawbone surgery and treated with RANTES 27CH. J Biol Regul Homeost Agents. 2018;32(1):37–45.
   Web of Science ®Google Scholar
• Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 1994;59(2):401–415.7516500
   PubMed Web of Science ®Google Scholar
• Cass WA, Harned ME, Bailey SL. Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats. Brain Res. 2002;938(1–2):29–37.12031532
   PubMed Web of Science ®Google Scholar
• Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson’s disease. J Neural Transm Suppl. 1995;46:297–314.8821067
   PubMedGoogle Scholar
• Schinelli S, Zuddas A, Kopin IJ, Barker JL, Di Porzio U. 1‐Methyl‐4‐Phenyl‐1, 2, 3, 6‐Tetrahydropyridine metabolism and l‐methyl‐4‐phenylpyridinium uptake in dissociated cell cultures from the embryonic mesencephalon. J Neurochem. 1988;50(6):1900–1907.3259619
   PubMed Web of Science ®Google Scholar
• Kuhar MJ, Couceyro PR, Lambert PD. Catecholamines. Basic Neurochem. 1999;243–261.
   Google Scholar
• Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo JIA. Glycogen synthase kinase 3β (GSK3β) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 2004;18(10):1162–1164. doi:10.1096/fj.04-1551fje15132987
   PubMed Web of Science ®Google Scholar
• Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272. doi:10.1016/S1474-4422(16)30230-727751556
   PubMed Web of Science ®Google Scholar
• Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(1):a008888. doi:10.1101/cshperspect.a00888822315721
   PubMed Web of Science ®Google Scholar
• Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Curr Environ Health Rep. 2017;4(2):192–199. doi:10.1007/s40572-017-0143-228417442
   PubMedGoogle Scholar
• Delamarre A, Meissner WG. Epidemiology, environmental risk factors and genetics of Parkinson’s disease. Presse Med. 2017;46(2 Pt 1):175–181. doi:10.1016/j.lpm.2017.01.00128189372
   PubMed Web of Science ®Google Scholar
• Parain K, Murer MG, Yan Q, et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. Neuroreport. 1999;10(3):557–561.10208589
   PubMed Web of Science ®Google Scholar
• Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A. 1994;91(11):5104–5108. doi:10.1073/pnas.91.11.51048197193
   PubMed Web of Science ®Google Scholar
• Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. J Neurosci. 1995;15(12):7810–7820.8613721
   PubMed Web of Science ®Google Scholar
• Schwartz PM, Borghesani PR, Levy RL, Pomeroy SL, Segal RA. Abnormal cerebellar development and foliation in BDNF−/− mice reveals a role for neurotrophins in CNS patterning. Neuron. 1997;19(2):269–281.9292718
   PubMed Web of Science ®Google Scholar
• Lui NP, Chen LW, Yung WH, Chan YS, Yung KKL. Endogenous repair by the activation of cell survival signalling cascades during the early stages of rat Parkinsonism. PLoS One. 2012;7(12):e51294. doi:10.1371/journal.pone.005129423251488
   PubMed Web of Science ®Google Scholar
• Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 2001;411(6833):86. doi:10.1038/3507507611333982
   PubMed Web of Science ®Google Scholar
• Chermenina M, Schouten P, Nevalainen N, Johansson F, Orädd G, Strömberg I. GDNF is important for striatal organization and maintenance of dopamine neurons grown in the presence of the striatum. Neuroscience. 2014;270:1–11. doi:10.1016/j.neuroscience.2014.04.00824726488
   PubMed Web of Science ®Google Scholar
• Henderson CE, Phillips HS, Pollock RA, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994;266(5187):1062–1064.7973664
   PubMed Web of Science ®Google Scholar
• Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson’s disease. Expert Rev Neurother. 2008;8(7):1125–1139. doi:10.1586/14737175.8.7.112518590482
   PubMedGoogle Scholar
• Clarkson ED, Zawada WM, Freed CR. GDNF reduces apoptosis in dopaminergic neurons in vitro. Neuroreport. 1995;7(1):145–149.8742438
   PubMed Web of Science ®Google Scholar
• Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Exp Neurol. 1996;141(1):32–39. doi:10.1006/exnr.1996.01368797665
   PubMed Web of Science ®Google Scholar
• Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons-a possible novel pathogenetic mechanism in Parkinson’s disease. Neurosci Lett. 1994;170(1):136–140.8041491
   PubMed Web of Science ®Google Scholar
• Quesada A, Romeo HE, Micevych P. Distribution and localization patterns of estrogen receptor‐β and insulin‐like growth factor‐1 receptors in neurons and glial cells of the female rat substantia nigra: localization of ERβ and IGF‐1R in substantia nigra. J Comp Neurol. 2007;503(1):198–208. doi:10.1002/cne.2135817480015
   PubMed Web of Science ®Google Scholar
• Kao SY. Rescue of α-synuclein cytotoxicity by insulin-like growth factors. Biochem Biophys Res Commun. 2000;385(3):434–438. doi:10.1016/j.bbrc.2009.05.089
   Web of Science ®Google Scholar
• Ueki T, Nakanishi K, Asai K, et al. Neurotrophic action of gliostatin on cocultured neurons with glial cells. Brain Res. 1993;622(1–2):299–302.8242371
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011;589(6):1251–1258. doi:10.1113/jphysiol.2010.19505721078592
   PubMed Web of Science ®Google Scholar
• Signore AP, Weng Z, Hastings T, et al. Erythropoietin protects against 6‐hydroxydopamine‐induced dopaminergic cell death. J Neurochem. 2006;96(2):428–443. doi:10.1111/j.1471-4159.2005.03587.x16336625
   PubMed Web of Science ®Google Scholar
• Xue YQ, Zhao LR, Guo WP, Duan WM. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson’s disease. Neuroscience. 2007;146(3):1245–1258. doi:10.1016/j.neuroscience.2007.02.00417363174
   PubMed Web of Science ®Google Scholar
• Kadota T, Shingo T, Yasuhara T, et al. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson’s disease model of rats with enhanced neurogenesis. Brain Res. 2009;1254:120–127. doi:10.1016/j.brainres.2008.11.09419101524
   PubMed Web of Science ®Google Scholar
• Erbaş O, Çınar BP, Solmaz V, Çavuşoğlu T, Ateş U. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides. 2015;49:1–5. doi:10.1016/j.npep.2014.10.00325464888
   PubMed Web of Science ®Google Scholar
• Ostenfeld T, Tai YT, Martin P, Déglon N, Aebischer P, Svendsen CN. Neurospheres modified to produce glial cell line‐derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res. 2002;69(6):955–965. doi:10.1002/jnr.1039612205689
   PubMed Web of Science ®Google Scholar
• Ebert AD, Barber AE, Heins BM, Svendsen CN. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington’s disease. Exp Neurol. 2010;224(1):155–162. doi:10.1016/j.expneurol.2010.03.00520227407
   PubMed Web of Science ®Google Scholar
• Barygina V, Becatti M, Lotti T, Taddei N, Fiorillo C. Low dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients. J Dermatol Sci. 2016;83(3):242–244. doi:10.1016/j.jdermsci.2016.06.00227317477
   PubMed Web of Science ®Google Scholar
• Mancini F, Milardi D, Carfagna P, et al. Low-dose SKA progesterone and Interleukin-10 modulate the inflammatory pathway in endometriotic cell lines. Int Immunopharmacol. 2018;55:223–230. doi:10.1016/j.intimp.2017.12.00829272819
   PubMed Web of Science ®Google Scholar